Month: February 2021

Influenza Vaccine Market 2021 Size & Share | Market worth USD 7.60 Billion at 6.9% CAGR by 2027

Written by Customer Service on February 8, 2021. Posted in Mergers And Acquisitions.

Pune, India, Feb. 08, 2021 (GLOBE NEWSWIRE) — According to the report, Influenza Vaccine market size is projected reach USD 7.34 billion by 2026. Global Influenza Vaccine market was USD 11.59 billion in 2018 and is anticipated to exhibit a CAGR of 6.9% during the forecast period set between 2019 to 2026. Influenza Vaccine market in North America was valued at USD 4.05 billion in 2018 and is also expected to observe the highest growth during forecast period.Increasing Demand for Flu Vaccine amid COVID-19 to Aid GrowthThe increasing focus on R&D activities to develop a vaccine to contain the widespread effect of the novel coronavirus is driving the demand for immunization across the globe. The COVID-19 pandemic has brought unprecedented changes in the healthcare industry. An increasing demand for the seasonal influenza vaccine...

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

Written by Customer Service on February 8, 2021. Posted in Public Companies.

– Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders –– CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation, and Degeneration 2021 conference on February 13, 2021 –ALPHARETTA, Ga., Feb. 08, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that numerous clinical presentations were delivered at the 44th Virtual Annual Macula Society Meeting which took place February 6-7, 2021. Clearside also announced that David M. Brown, M.D. will deliver a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD”...

uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Written by Customer Service on February 8, 2021. Posted in Public Companies.

~ No Significant Safety Concerns Observed ~~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment ~~ Full Enrollment of First Cohort Expected Mid-2021 ~LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 08, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease has met and reviewed the six-month safety data from the first two enrolled patients and the 90-day safety data from the next two enrolled patients in the study. No significant safety concerns were noted to prevent further dosing, and the final six patients in the first cohort...

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

Written by Customer Service on February 8, 2021. Posted in Public Companies.

New Analysis Published in Psychiatry ResearchSALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight® Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.Myriad’s GeneSight test evaluates how variations in multiple genes may influence an individual’s outcomes with certain FDA-approved medications commonly prescribed to treat depression, anxiety, and other psychiatric conditions.Using data from the Genomics Used to Improve DEpression Decisions (GUIDED) randomized-controlled trial, the study evaluated the ability of the combinatorial approach...

Bicycle Market to witness significant growth at a healthy 5.02% CAGR | Market Research Future (MRFR)

Written by Customer Service on February 8, 2021. Posted in Mergers And Acquisitions.

Pune, Feb. 08, 2021 (GLOBE NEWSWIRE) — Bicycle Market Analysis/Bicycle Market Outlook The global bicycle industry is highly lucrative and predicted to witness significant growth at a healthy 5.02% CAGR over the forecast period. reveals the Market Research Future (MRFR) report. People worldwide are becoming more and more fitness freaks that in turn are boosting the demand for bicycles as an alternative mode of transport. The demand for e-bicycles over conventional bicycles is evolving and has turned mainstream. Today bicycles are available in different types, such as all-terrain bicycles, hybrid bicycles, and road bicycles, among others. Attractive Features that Boost Market Growth As per the Market Research Future report, there are numerous factors that are propelling the global bicycle market size. These include rising public bike-sharing...

Cerence Announces Record First Quarter 2021 Results

Written by Customer Service on February 8, 2021. Posted in Earnings Releases And Operating Results.

Won back a major European OEM’s next generation infotainment design for cars starting production in 2023First major bookings for new applications including Cerence PayRevenue grew by 23% compared to the same period last fiscal year, setting a new quarterly recordExceeded company quarterly guidance on all GAAP and non-GAAP financial metricsContinued to deliver strong GAAP Net Income and Adjusted EBITDA performanceGrowth in billings per car continues its upward trendBURLINGTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today reported its first fiscal quarter 2021 results for the quarter ended December 31, 2020.Results Summary (1)(in millions, except per share data)(1) Please refer to the “Discussion of Non-GAAP Financial Measures” and “Reconciliations of GAAP Financial Measures...

Abacus Announces Start of Jersey Valley Drilling

Written by Customer Service on February 8, 2021. Posted in Public Companies.

VANCOUVER, British Columbia, Feb. 08, 2021 (GLOBE NEWSWIRE) — Abacus Mining & Exploration Corporation (“Abacus” or the “Company”) (TSXV: AME) is pleased to announce that a diamond drilling program is about to begin at Jersey Valley, within the Battle Mountain trend of north-central Nevada.The Company has signed a contract for approximately 1100 metres of core drilling, designed to test two of the five anomalous trends identified in the Induced Polarization (IP) geophysical survey completed late last year. Four holes will be drilled, ranging in depth from 250 to 300 metres.The IP survey detected 44 separate targets, which have been grouped into five separate ENE trending zones, four of which are open in at least one direction. Three zones have signatures characteristic of epithermal precious metal mineralization and two others...

Annexon Welcomes William H. Carson, M.D. to the Board of Directors

Written by Customer Service on February 8, 2021. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) — Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced the appointment of William H. Carson, M.D. to its board of directors. Concurrently with Dr. Carson’s appointment, Thomas G. Wiggans has been appointed Annexon’s chairman, as William Young and Carol Gallagher, PharmD, retire from the board on February 5, 2021.Dr. Carson brings deep expertise in pharmaceutical research, development and commercialization, with specialization in central nervous system (CNS) disorders. Most recently he was the president and CEO of Otsuka Pharmaceutical Development & Commercialization,...

Talenom Oyj:n tilinpäätöstiedote 2020 (tilintarkastettu): Liikevoitto parani 23,8 % ja liikevaihto kasvoi 12,4 % – Kasvunäkymät laajenevat ja kannattavuus säilyy erinomaisena

Written by Customer Service on February 8, 2021. Posted in Earnings Releases And Operating Results.

Talenom Oyj, Tilinpäätöstiedote 8.2.2021 klo 13:30Talenom Oyj:n tilinpäätöstiedote 2020 (tilintarkastettu): Liikevoitto parani 23,8 % ja liikevaihto kasvoi 12,4 % – Kasvunäkymät laajenevat ja kannattavuus säilyy erinomaisena

Talenom Plc Financial Statement Bulletin 2020 (audited): Operating profit improved by 23.8% and net sales grew by 12.4% – Outlook for growth broadens and profitability remains excellent

Written by Customer Service on February 8, 2021. Posted in Earnings Releases And Operating Results.

Talenom Plc, Financial Statement Release, 8 February 2021 at 13:30 EETTalenom Plc Financial Statement Bulletin 2020 (audited): Operating profit improved by 23.8% and net sales grew by 12.4% – Outlook for growth broadens and profitability remains excellent

Month: February 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals